Literature DB >> 27698508

Elbasvir/Grazoprevir.

Dennis J Cada, Anne P Kim, Danial E Baker.   

Abstract

Each month, subscribers to The Formulary Monograph Service receive 5 to 6 well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to Pharmacy & Therapeutics Committees. Subscribers also receive monthly 1-page summary monographs on agents that are useful for agendas and pharmacy/nursing in-services. A comprehensive target drug utilization evaluation/medication use evaluation (DUE/MUE) is also provided each month. With a subscription, the monographs are available online to subscribers. Monographs can be customized to meet the needs of a facility. Through the cooperation of The Formulary, Hospital Pharmacy publishes selected reviews in this column. For more information about The Formulary Monograph Service, contact Wolters Kluwer customer service at 866-397-3433. The September 2016 monograph topics are barictinib, buprenorphine implants, sarilumab, sofosbuvir/velpatasvir, and cholera vaccine, live, oral. The Safey MUE is on sofosbuvir/velpatasvir.

Entities:  

Year:  2016        PMID： 27698508      PMCID： PMC5030880          DOI： 10.1310/hpj5108-665

Source DB:  PubMed          Journal:  Hosp Pharm        ISSN： 0018-5787


  16 in total

1.  A SPECIAL MEETING REVIEW EDITION: Advances in the Treatment of Hepatitis C Virus Infection From EASL 2015: The 50th Annual Meeting of the European Association for the Study of the Liver • April 22-26, 2015 • Vienna, AustriaSpecial Reporting on:• Daclatasvir, Sofosbuvir, and Ribavirin Combination for HCV Patients With Advanced Cirrhosis or Posttransplant Recurrence: Phase 3 ALLY-1 Study• Efficacy and Safety of Grazoprevir and Elbasvir in Hepatitis C Genotype 1-Infected Patients With Child-Pugh Class B Cirrhosis (C-SALT Part A)• Ledipasvir/Sofosbuvir With Ribavirin Is Safe and Efficacious in Decompensated and Post Liver Transplantation Patients With HCV Infection: Preliminary Results of the Prospective SOLAR 2 Trial• Retreatment of Patients Who Failed 8 or 12 Weeks of Ledipasvir/Sofosbuvir-Based Regimens With Ledipasvir/Sofosbuvir for 24 Weeks• Sofosbuvir + Peginterferon/Ribavirin for 12 Weeks Vs Sofosbuvir + Ribavirin for 16 or 24 Weeks in Genotype 3 HCV Infected Patients and Treatment-Experienced Cirrhotic Patients With Genotype 2 HCV: The BOSON Study• Safety and Efficacy of the Combination Daclatasvir-Sofosbuvir in HCV Genotype 1-Mono-Infected Patients From the French Observational Cohort ANRS CO22 HEPATHER• C-SWIFT: Grazoprevir/Elbasvir + Sofosbuvir in Cirrhotic and Noncirrhotic, Treatment-Naive Patients With Hepatitis C Virus Genotype 1 Infection for Durations of 4, 6 or 8 Weeks and Genotype 3 Infection for Durations of 8 or 12 WeeksPLUS Meeting Abstract Summaries With Expert Commentary by: Steven L. Flamm, MD Chief, Liver Transplantation ProgramProfessor of Medicine and SurgeryNorthwestern University Feinberg School of MedicineChicago, Illinois.

Authors: 
Journal:  Gastroenterol Hepatol (N Y)       Date:  2015-06

Review 2.  MK-5172 : a second-generation protease inhibitor for the treatment of hepatitis C virus infection.

Authors:  Ivan Gentile; Antonio Riccardo Buonomo; Federico Borgia; Emanuela Zappulo; Giuseppe Castaldo; Guglielmo Borgia
Journal:  Expert Opin Investig Drugs       Date:  2014-03-26       Impact factor: 6.206

Review 3.  Drug-Drug Interactions With Antiviral Agents in People Who Inject Drugs Requiring Substitution Therapy.

Authors:  Leonie Meemken; Nikola Hanhoff; Alice Tseng; Stefan Christensen; Anton Gillessen
Journal:  Ann Pharmacother       Date:  2015-04-22       Impact factor: 3.154

Review 4.  Antiviral activity and resistance of HCV NS5A replication complex inhibitors.

Authors:  Min Gao
Journal:  Curr Opin Virol       Date:  2013-07-27       Impact factor: 7.090

5.  Efficacy and safety of 8 weeks versus 12 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin in patients with hepatitis C virus genotype 1 mono-infection and HIV/hepatitis C virus co-infection (C-WORTHY): a randomised, open-label phase 2 trial.

Authors:  Mark Sulkowski; Christophe Hezode; Jan Gerstoft; John M Vierling; Josep Mallolas; Stanislas Pol; Marcelo Kugelmas; Abel Murillo; Nina Weis; Ronald Nahass; Oren Shibolet; Lawrence Serfaty; Marc Bourliere; Edwin DeJesus; Eli Zuckerman; Frank Dutko; Melissa Shaughnessy; Peggy Hwang; Anita Y M Howe; Janice Wahl; Michael Robertson; Eliav Barr; Barbara Haber
Journal:  Lancet       Date:  2014-11-11       Impact factor: 202.731

6.  Grazoprevir-Elbasvir Combination Therapy for Treatment-Naive Cirrhotic and Noncirrhotic Patients With Chronic Hepatitis C Virus Genotype 1, 4, or 6 Infection: A Randomized Trial.

Authors:  Stefan Zeuzem; Reem Ghalib; K Rajender Reddy; Paul J Pockros; Ziv Ben Ari; Yue Zhao; Deborah D Brown; Shuyan Wan; Mark J DiNubile; Bach-Yen Nguyen; Michael N Robertson; Janice Wahl; Eliav Barr; Joan R Butterton
Journal:  Ann Intern Med       Date:  2015-07-07       Impact factor: 51.598

7.  Grazoprevir, Elbasvir, and Ribavirin for Chronic Hepatitis C Virus Genotype 1 Infection After Failure of Pegylated Interferon and Ribavirin With an Earlier-Generation Protease Inhibitor: Final 24-Week Results From C-SALVAGE.

Authors:  Maria Buti; Stuart C Gordon; Eli Zuckerman; Eric Lawitz; Jose L Calleja; Harald Hofer; Christopher Gilbert; John Palcza; Anita Y M Howe; Mark J DiNubile; Michael N Robertson; Janice Wahl; Eliav Barr; Xavier Forns
Journal:  Clin Infect Dis       Date:  2015-09-14       Impact factor: 20.999

8.  Efficacy and safety of grazoprevir (MK-5172) and elbasvir (MK-8742) in patients with hepatitis C virus and HIV co-infection (C-EDGE CO-INFECTION): a non-randomised, open-label trial.

Authors:  Jürgen K Rockstroh; Mark Nelson; Christine Katlama; Jay Lalezari; Josep Mallolas; Mark Bloch; Gail V Matthews; Michael S Saag; Philippe J Zamor; Chloe Orkin; Jacqueline Gress; Stephanie Klopfer; Melissa Shaughnessy; Janice Wahl; Bach-Yen T Nguyen; Eliav Barr; Heather L Platt; Michael N Robertson; Mark Sulkowski
Journal:  Lancet HIV       Date:  2015-07-09       Impact factor: 16.070

9.  Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection.

Authors:  Jordan J Feld; Ira M Jacobson; Christophe Hézode; Tarik Asselah; Peter J Ruane; Norbert Gruener; Armand Abergel; Alessandra Mangia; Ching-Lung Lai; Henry L Y Chan; Francesco Mazzotta; Christophe Moreno; Eric Yoshida; Stephen D Shafran; William J Towner; Tram T Tran; John McNally; Anu Osinusi; Evguenia Svarovskaia; Yanni Zhu; Diana M Brainard; John G McHutchison; Kosh Agarwal; Stefan Zeuzem
Journal:  N Engl J Med       Date:  2015-11-16       Impact factor: 91.245

10.  Sofosbuvir and Velpatasvir for HCV in Patients with Decompensated Cirrhosis.

Authors:  Michael P Curry; Jacqueline G O'Leary; Natalie Bzowej; Andrew J Muir; Kevin M Korenblat; Jonathan M Fenkel; K Rajender Reddy; Eric Lawitz; Steven L Flamm; Thomas Schiano; Lewis Teperman; Robert Fontana; Eugene Schiff; Michael Fried; Brian Doehle; Di An; John McNally; Anu Osinusi; Diana M Brainard; John G McHutchison; Robert S Brown; Michael Charlton
Journal:  N Engl J Med       Date:  2015-11-16       Impact factor: 91.245
View more
  2 in total

Review 1.  Era of direct acting anti-viral agents for the treatment of hepatitis C.

Authors:  Monjur Ahmed
Journal:  World J Hepatol       Date:  2018-10-27

Review 2.  Carbamate group as structural motif in drugs: a review of carbamate derivatives used as therapeutic agents.

Authors:  Ana Matošević; Anita Bosak
Journal:  Arh Hig Rada Toksikol       Date:  2020-12-31       Impact factor: 2.078
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.